PH
PHAT.US Phathom Pharmaceuticals Inc
- Market cap
- USD 478M
- P/E
- -
- P/B
- 25.37x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PHAT.US undervalued?
Graham numberThe Graham number of Phathom Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Phathom Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Phathom Pharmaceuticals Inc yet.
Phathom Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA…
Full company profilePhathom Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Phathom Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 682K | 55.3M | 175M | 290M |
| Gross Profit | - | -8.00K | -300K | -521K | -620K | 515K | 47.3M | 153M | 229M |
| Operating Income | -1.23M | -106M | -126M | -135M | -172M | -167M | -277M | -160M | -26.0M |
| EBITDA | -50.0K | -251M | -124M | -137M | -170M | -159M | -262M | -152M | -20.3M |
| Net Income | -1.29M | -210M | -129M | -144M | -198M | -202M | -334M | -221M | -82.5M |
| EPS | -0.15 | -8.48 | -3.88 | -3.89 | -5.05 | -3.93 | -5.29 | -3.03 | -0.97 |
| Balance Sheet | |||||||||
| Total Assets | 902K | 257M | 295M | 189M | 165M | 414M | 378M | 259M | 345M |
| Total Liabilities | 2.19M | 29.2M | 101M | 117M | 240M | 487M | 632M | 697M | 693M |
| Shareholders' Equity | -1.29M | 228M | 194M | 72.2M | -74.8M | -72.8M | -254M | -438M | -348M |
| Cash & Short-term Investments | 879K | 244M | 287M | 183M | 155M | 381M | 297M | 130M | 185M |
| Total Debt | 1.95M | 23.6M | 49.0M | 91.3M | 97.1M | 139M | 202M | 212M | 168M |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.02M | -36.5M | -69.7M | -148M | -147M | -138M | -267M | -167M | -21.0M |
| Capital Expenditure | 132K | 25.3M | 1.04M | 328K | 1.04M | 1.63M | 135K | 229K | 287K |
| Free Cash Flow | -1.16M | -61.8M | -70.7M | -149M | -148M | -139M | -267M | -167M | -21.3M |
| Ratios | |||||||||
| ROE | - | -92.0% | -66.4% | -199.4% | - | - | - | - | - |
| ROA | -142.8% | -81.6% | -43.7% | -76.0% | -120.0% | -48.7% | -88.4% | -85.4% | -23.9% |
| Net Profit Margin | - | - | - | - | - | -29,558.9% | -605.1% | -126.3% | -28.5% |
| Debt to Equity | - | 0.10x | 0.25x | 1.27x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Phathom Pharmaceuticals Inc dividends
Phathom Pharmaceuticals Inc has not paid dividends in the last 8 fiscal years.
Who owns Phathom Pharmaceuticals Inc
- Insiders 4.99%
- Institutions 90.45%
- Public & others 4.56%
- Shares outstanding 81.3M
- Free float 65.6M
Top funds holding PHAT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.01M | 2.47% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 1.36M | 1.67% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.25M | 1.54% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 939K | 1.16% | 0.00% | Sep 2026 |
| Wasatch Small Cap Growth Investor | 841K | 1.03% | 0.00% | Sep 2026 |
| Franklin Small Cap Growth Adv | 827K | 1.02% | 0.00% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 782K | 0.96% | +0.02% | Aug 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 725K | 0.89% | +2.88% | Oct 2026 |
| HSBC GIF Glb Eq Sust Hlthcare AC USD | 700K | 0.86% | 0.00% | Aug 2026 |
| Columbia Small Cap Value Discv A | 669K | 0.82% | +19.93% | Sep 2026 |
| Wasatch Micro Cap | 625K | 0.77% | -22.51% | Sep 2026 |
| Fidelity Small Cap Index | 545K | 0.67% | +1.63% | Aug 2026 |
| Franklin Biotechnology Discovery A | 507K | 0.62% | 0.00% | Sep 2026 |
| Wasatch Ultra Growth | 462K | 0.57% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 398K | 0.49% | -0.19% | Oct 2026 |
| JNL/Invesco Global Growth A | 337K | 0.42% | +17.01% | Mar 2026 |
| iShares Russell 2000 Value ETF | 334K | 0.41% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 305K | 0.38% | +0.23% | Oct 2026 |
| Vanguard Russell 2000 ETF | 290K | 0.36% | +2.61% | Sep 2026 |
| Fidelity Extended Market Index | 281K | 0.35% | +9.36% | Sep 2026 |
Top institutions holding PHAT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12.5M | 15.34% | 0.00% | Jun 2026 |
| Medicxi Ventures Management (Jersey) Ltd | 7.46M | 9.18% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.53M | 5.57% | +11.40% | Jun 2026 |
| Amvescap Plc. | 4.03M | 4.96% | -6.76% | Jun 2026 |
| The Carlyle Group Inc | 3.50M | 4.30% | 0.00% | Jun 2026 |
| Millennium Management LLC | 3.38M | 4.15% | -16.08% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.66M | 3.27% | +2.84% | Jun 2026 |
| GW&K Investment Management, LLC | 2.17M | 2.67% | +52.48% | Jun 2026 |
| Franklin Templeton Inc | 1.97M | 2.42% | +98.17% | Jun 2026 |
| NEA Management Company, LLC | 1.96M | 2.41% | 0.00% | Jun 2026 |
| Catalys Pacific LLC | 1.88M | 2.32% | +25.99% | Sep 2026 |
| The Goldman Sachs Group Inc | 1.78M | 2.19% | +183.94% | Jun 2026 |
| State Street Corp | 1.59M | 1.95% | +14.38% | Jun 2026 |
| Delaware Management Holdings Inc | 1.46M | 1.80% | +21.35% | Jun 2026 |
| Geode Capital Management, LLC | 1.32M | 1.62% | -0.93% | Jun 2026 |
| Wasatch Advisors LP | 1.31M | 1.61% | -2.51% | Jun 2026 |
| Ensign Peak Advisors Inc | 1.05M | 1.29% | -35.38% | Jun 2026 |
| Propel Bio Management LLC | 1.05M | 1.29% | +24.85% | Jun 2026 |
| Point72 Asset Management, L.P. | 1.02M | 1.26% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 797K | 0.98% | +19.61% | Jun 2026 |
Phathom Pharmaceuticals Inc company profile
- Company name
- Phathom Pharmaceuticals Inc
- Ticker
- PHAT.US
- Exchange
- USA Stocks
- Listed since
- Oct 25, 2019
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 371
- Fiscal year end
- December
- Address
- 100 Campus Drive, Florham Park, NJ, United States, 07932
- Phone
- 877 742 8466
- Website
- phathompharma.com
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals Inc management
10- Mr. Steven L. Basta M.B.A.CEO, President & Director · born 1966
- Mr. David A. SocksCo-Founder · born 1975
- Dr. Azmi Nabulsi M.D., M.P.H.Co-Founder · born 1960
- Mr. Sanjeev NarulaChief Financial & Business Officer · born 1961
- Ms. Anne Marie Cook Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1962
- Mr. Jonathan BentleySenior VP and Head of Sales, Operations & Training
- Mr. Robert BreedloveVP of Finance & Principal Accounting Officer
- Mr. Eric SciorilliDirector of Business Development & Investor Relations
- Mr. Bill Aprea J.D.Senior VP, Chief Compliance Officer & Deputy Chief Legal Officer
- Mr. Paul CocjaChief People Officer